Success Story: NIW Approval Secured for Cancer Immunology Research Advancing Precision T-Cell Therapies
Client’s Testimonial:
"I am very happy to share my experience with my successful EB-2 NIW journey. I had heard about Chen Immigration from a few of my friends and, after comparing different law firms, I decided to work with them. Overall, it was an excellent experience. The process takes time and requires a lot of effort, but I truly appreciated how carefully the attorney and the entire team reviewed even the smallest details of my research and petition. The team was very thorough, trusted my research, and worked hard to make sure my petition was as strong as possible.
As a cancer immunology researcher, getting my NIW approved through premium processing is a major milestone for my career and gives me the flexibility to continue my research in the United States. I am truly grateful to the entire Chen Immigration team for their patience, expertise, and support throughout this journey. I would definitely recommend them to other researchers who are considering an EB-2 NIW.”
On July 28th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Cancer Immunology (Approval Notice).
General Field: Cancer Immunology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: India
State of Residence at the Time of Filing: Ohio
Approval Notice Date: July 28th, 2026
Processing Time: 2 months, 1 day (Premium Processing Requested)
Case Summary:
We received another I-140 National Interest Waiver (NIW) approval through premium processing for a researcher in the field of cancer immunology. The client holds a Ph.D. in biotechnology and sought to continue conducting research that addresses one of today's most significant challenges in cancer treatment: improving the precision, durability, and safety of immunotherapies for multiple myeloma and related cancers. Through a carefully prepared petition, North America Immigration Law Group demonstrated that the client's proposed endeavor satisfies the NIW framework by addressing work of substantial merit and national importance while establishing that the client is well positioned to continue advancing the field.
The client's proposed endeavor focuses on engineering human T cells to better target multiple myeloma and related cancers in order to enhance therapy durability, minimize toxicity, and drive innovation in precision medicine. At the time of filing, the client was conducting cancer immunology research as a research associate and had plans to continue pursuing this line of research in a subsequent research scientist position. The petition explained that this work contributes to the development of more effective immunotherapies capable of overcoming treatment resistance while improving outcomes for patients affected by hematologic cancers.
To establish that the client was well positioned to advance the proposed endeavor, the petition presented a comprehensive record of scholarly achievement. The client had authored 11 peer-reviewed journal articles, including 5 first- or co-first-authored publications, as well as 3 research abstracts. These publications had accumulated 84 citations, demonstrating that independent researchers had relied upon the client's findings in their own work. Rather than relying solely on publication and citation metrics, the petition explained how the client's research had informed subsequent investigations in cancer immunology, immunotherapy, and related biomedical disciplines, illustrating meaningful influence within the scientific community. In addition, the client had completed at least 11 peer reviews for recognized scientific journals, reflecting that respected publication venues trusted the client's expertise to evaluate the work of fellow researchers.
The petition also demonstrated the broader significance of the client's work by showing how the research aligned with national priorities in cancer treatment, biotechnology, and precision medicine. Independent evidence established that the client's investigations into engineered T-cell therapies addressed important clinical challenges while contributing to the development of next-generation immunotherapy strategies. Furthermore, the petition highlighted that the client's research had received competitive funding from both the National Cancer Institute and the U.S. Department of Veterans Affairs, supporting the argument that the research had already been recognized for its importance in advancing public health and biomedical innovation.
By presenting evidence of advanced academic training, an impactful research agenda, sustained scholarly contributions, peer recognition, competitive research funding, and a clear plan for future work, the petition established that waiving the job offer and labor certification requirements would benefit the United States. USCIS approved the client's NIW petition through premium processing, recognizing the client's ability to continue advancing research that supports the future of precision cancer immunotherapy and improved treatment options for patients.